View
0
Download
0
Category
Preview:
Citation preview
3,400+employees
(as of January 29, 2020)
Trials in 35countries and regions
10 officeson 4 continents
The BeiGene StoryA global biopharmaceutical innovator focused on improving treatment outcomes and patient access
BeiGene is a fully-integrated biopharmaceutical
company co-founded in 2010 by John Oyler, an
American entrepreneur, and Dr. Xiaodong Wang,
one of the youngest ever U.S. Academy of Science
members and Director of China’s National Institute
of Biological Sciences (NIBS) in Beijing. The two set
out to build a unique company that was globally
focused from its inception.
BeiGene (NASDAQ: BGNE; HKEX 06160) focuses on
developing novel cancer therapies where there is
global unmet need.
Our broad product portfolio and pipeline include:
• 3 wholly owned late-stage oncology candidates,
including one approved in the U.S. and one
approved in China
• 27 Phase 3 or potentially registration-enabling
trials ongoing, 60+ studies in total
• 32 clinical or commercial stage assets including
seven internally developed and 25 in-licensed
BeiGene has built a strong innovative pipeline of
clinical drug candidates through internal discovery
and collaborations.
Transformative Collaboration with Amgen
This global strategic oncology collaboration expands
access to important oncology medicines for patients
in China and around the globe with:
• BeiGene commercializing three Amgen oncology
products in China — XGEVA® (denosumab),
KYPROLIS™ (carfilzomib), and BLINCYTO®
(blinatumomab)
• Companies jointly developing 20 Amgen
oncology pipeline assets globally, with BeiGene
leading development in China
• Amgen investing $2.8B for a 20.5%
stake in BeiGene
1Abbreviated pipeline as of January 9, 2020. For full pipeline, visit beigene.com/science-and-product-portfolio/pipeline
• Investigational KRASG12C small molecule inhibitor • In-licensed from Amgen, rights in China
• Investigational humanized lgG1-variant monoclonal antibody against TIM-3• Currently being investigated in combination with tislelizumab in solid tumors
• Investigational spectrum-selective kinase inhibitor of receptor tyrosine kinases, including RET, TAM family receptors (TYRO3, Axl, MER) and split family receptors (VEGFR2, KIT)
• Currently being investigated in combination with tislelizumab in solid tumors• In-licensed from Mirati Therapeutics, rights in Asia ex-Japan, AU, NZ
• Investigational TIGIT monoclonal antibody • Currently being investigated as in combination with tislelizumab in solid tumors
• Investigational small molecule Bcl-2 inhibitor • Currently being investigated as a monotherapy and in combination with zanubrutinib in
hematologic malignancies
• Investigational HER2-targeted bispecific antibody • Currently being investigated in combination with tislelizumab in solid tumors • In-licensed from Zymeworks, rights in Asia ex-Japan, AU, NZ
• Investigational HER2-targeted bispecific antibody drug conjugate (ADC)• In-licensed from Zymeworks, rights in Asia ex-Japan, AU, NZ
BGB-A425
BGB-A1217
BGB-11417
Sitravatinib
ZW25
ZW49
AMG 510
• Potent second generation small molecule inhibitor of Bruton’s tyrosine kinase • Currently being investigated as a monotherapy and in combination with other
therapies in multiple hematologic malignancies
• Investigational novel small molecule inhibitor with RAF monomer and dimer inhibition activities • Currently being investigated as a monotherapy and in combination with mirdametinib (MEK
inhibitor from SpringWorks Therapeutics) in solid tumors
• Investigational humanized monoclonal antibody against the immune checkpoint receptor ligand PD-L1
• Currently being investigated as a monotherapy and in combination with tislelizumab in solid tumors
• Investigational small molecule inhibitor of PARP1 and PARP2• Currently being investigated as a monotherapy and in combination with other therapies
in multiple solid tumors
• Humanized IgG4 anti-PD-1 monoclonal antibody • Currently being investigated as a monotherapy and in combination with other therapies
in multiple solid tumors and hematologic malignancies
Zanubrutinib
Tislelizumab
Pamiparib
Lifirafenib
BGB-A333
BEIGENE’S SELECTED INVESTIGATIONAL PIPELINE1
• China NMPA approvals in R/R multiple myeloma and multiple myeloma• In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China
• China NMPA approval in breast cancer • In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China
• China NMPA approvals in myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia
• In-licensed from Celgene (a Bristol-Myers Squibb) company, rights in China
REVLIMID® (lenalidomide)
VIDAZA® (azacitidine)
ABRAXANE® (albumin-bound paclitaxel)
BRUKINSA™ (zanubrutinib)
Tislelizumab
• U.S. FDA accelerated approval in November 2019 for relapsed/ refractory (R/R) mantle cell lymphoma
• China NMPA approval in giant cell tumor of bone• In-licensed from Amgen, rights in China
• China NMPA approval in R/R classical Hodgkin’s lymphoma
XGEVA® (denosumab)
BEIGENE’S COMMERCIAL PRODUCT PORTFOLIO
BeiGene’s commitment is to never compromise
on the safety, compliance, or quality of our
products, our research, or our services. We are
focused on serving patients by delivering quality
drug products that consistently meet or exceed all
customer and regulatory requirements. Each
BeiGene employee and partner is responsible for
achieving our objectives and for looking at any
opportunity where we can improve upon our high
standards of performance.
BeiGene conducts its clinical trials in accordance
with the regulatory requirements of the U.S. Food
and Drug Administration (FDA), the European
Medicines Agency (EMA), and the China National
Medical Products Administration (NMPA), as
applicable. Likewise, BeiGene’s own state-of-the-art
manufacturing facilities, located in China, are fully
compliant with Good Manufacturing Practice (GMP)
requirements of the U.S., European and Chinese
authorities and subject to inspection and approval
by these authorities. It has also contracted with
leading American and German manufacturers for
production of its drug candidates.
Our Commitment
BeiGene employees are dedicated to translating groundbreaking science into quality innovative cancer therapies.
With a global headcount of over 3,400 employees, more than 1,000 are devoted to global clinical development and approximately 1,000 are in commercial operation.
John V. OylerChairman, Founder & CEOBioDuro, Galenea, Telephia, Genta, McKinsey & Company
Xiaodong Wang, Ph.D.Founder & Chairman SABNIBS: National Institute of Biological Sciences in Beijing, UT Southwestern Medical Center, Howard Hughes Medical Institute, National Academy of Sciences
Yong (Ben) Ben, M.D.CMO, Immuno-OncologyBioAtla, AstraZeneca
Josh NeimanHead of U.S. Commercial Flatiron Health, Onyx Pharmaceuticals, Genentech
Jane Huang, M.D.CMO, HematologyAcerta, Genentech
Todd Yancey, M.D.SVP, Global Medical Affairs & New Market DevelopmentBioMarin, Clovis Oncology, Medivation, Onyx Pharmaceuticals
Xiaobin Wu, Ph.D.GM of China & President Pfizer, Wyeth, Bayer
Eric Hedrick, M.D.Chief AdvisorGenentech, Pharmacyclics, Epizyme
Guillaume Vignon, Ph.D.SVP, Business DevelopmentMerck KGaA
Lai Wang, Ph.D.SVP, Head of Global Research, Clinical Operation, Biometrics & APAC Clinical DevelopmentJoyant Pharmaceuticals, Howard Hughes Medical Institute
Meet Members of Our Leadership Team
www.beigene.com
@BeiGeneUSA
Our employees look forward to connecting with youto provide additional insight into BeiGene.
Contact us at: 888-123-4455 or info@beigene.com
©2020 BeiGene, Inc.
Recommended